Medico Remedies Ltd

Medico Remedies Ltd has responded to a query dated September 29th, 2026, stating that there is no pending information or announcement required to be disclosed under SEBI (LODR) Regulations, 2015, or any other event bearing on the company's operations or performance. The company attributes any price and volume movement in its shares purely to market conditions and states that it regularly shares all material information and events with the stock exchange as required.

Medico Remedies Ltd has announced the closure of its trading window for all insiders, designated persons, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut from October 1st, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended September 30th, 2026. This measure is standard practice to prevent potential insider trading activities around financial result announcements.

Medico Remedies Ltd has announced its 32nd Annual General Meeting (AGM) to be held on September 22, 2026, at 4:00 PM via Video Conferencing. The agenda includes the adoption of the Audited Financial Statements for the fiscal year 2025-26, the reappointment of Mr. Haresh Kapurlal Mehta as Director retiring by rotation, and the special business of re-appointing Mr. Rishit Mehta as Whole-Time Director for a further period of three years from September 18, 2026, with a monthly remuneration not exceeding ₹7,50,000. The company also submitted its Annual Report for FY 2025-26.

Medico Remedies Ltd has announced its 32nd Annual General Meeting (AGM) to be held on Tuesday, September 22, 2026, at 4:00 p.m. via Video Conferencing. The meeting will focus on adopting the Audited Financial Statements for the fiscal year 2025-26, along with the Board and Auditors' reports. Key agenda items include the re-appointment of Mr. Haresh Kapurlal Mehta as a Director retiring by rotation and the special business of re-appointing Mr. Rishit Mehta as Whole-Time Director for a further period of three years from September 18, 2026, with a monthly remuneration not exceeding ₹7,50,000, plus benefits and perquisites. The company also submitted its Annual Report for FY 2025-26.

Medico Remedies Ltd has responded to a query regarding price and volume movements in its shares. The company stated that there is no pending information or announcement required under SEBI (LODR) Regulations, 2015, or any other event impacting operations or performance. They clarified that any fluctuations in share price are purely market-driven and due to market conditions. Medico Remedies affirmed its commitment to regularly disclosing all material information and events to the stock exchange as required.

Medico Remedies posted standalone revenue from operations of ₹69.40 Cr in Q1FY27 (quarter ended 30 June 2026), up 81.4% YoY from ₹38.25 Cr and up 22.2% QoQ from ₹56.81 Cr. Net profit rose 38.5% YoY to ₹2.52 Cr (from ₹1.82 Cr) but fell 57.0% QoQ from ₹5.86 Cr — the topline surge did not flow through proportionately to the bottom line, with profit growth trailing revenue growth by more than 40 percentage points YoY. Basic EPS was ₹0.30 versus ₹0.22 a year ago and ₹0.71 in the preceding quarter. The gap is a margin story. Net profit margin (PAT/total income) compressed to 3.57% from 4.67% YoY and 9.81% QoQ; operating margin (EBITDA/revenue) fell to 4.76% from 7.39% YoY and 12.59% QoQ. The main driver sits in the cost base: the company recognised a ₹7.36 Cr charge from changes in inventories of finished/WIP goods this quarter (inventory drawdown) versus a ₹2.00 Cr credit (inventory build) in Q1FY26 — a roughly ₹9.35 Cr swing on a ~₹67 Cr expense base, and the single largest driver of the squeeze. Raw material cost rose 64.4% YoY to ₹47.20 Cr, a slower pace than the 81.4% revenue growth, which cushioned but did not offset the inventory-line drag. There are no exceptional items or minority interest in the statement, so raw and adjusted YoY PAT growth are identical at 38.5%. Medico gives no formal guidance, and our records show no prior concall commentary to benchmark against, so vsGuidance is unknown; a web search turned up no analyst previews or consensus estimates for this micro-cap (searches returned coverage for the similarly named Indoco Remedies instead), so street comparison is also unknown. The filing carries no separate management press release or MD&A commentary beyond the standard board notes. Notably, the quarter's geographic mix shifted sharply: domestic sales jumped to ₹26.34 Cr (38% of the segment total) from just ₹2.74 Cr in Q4FY26, while exports fell 20.4% QoQ to ₹42.70 Cr from ₹53.64 Cr — a reversal of the export-heavy mix seen last quarter, with no management explanation given in the notes. Concurrent board actions from the same meeting included re-appointing Rishit Mehta and Haresh Mehta as whole-time directors (effective 18 September 2026) and raising MD Harshit Mehta's remuneration; a minor ₹1.13 lakh NSE/BSE fine for a listing-rule violation was disclosed earlier in the quarter (3 June 2026) but is immaterial to the P&L. The $1.4M (~₹11.7 Cr) government supply order announced 5 August 2026 falls into Q2FY27 and, combined with the domestic-sales surge already visible this quarter, is the marker to watch for whether the mix shift toward domestic sales continues. Whether the inventory-drawdown-driven margin compression reverses — OPM returning toward the 7-12% band seen in the trailing two quarters — is the other open question heading into next quarter.

Medico Remedies Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the accompanying limited review report. The meeting will also address any other business as permitted by the Chair. This meeting is a routine procedural step for the company to finalize and present its quarterly financial performance.

Medico Remedies Ltd has announced securing a significant government supply order valued at USD 1,406,450 (approximately INR 13.38 Crores) from PROMESE/CAL in the Dominican Republic. The order involves the supply of tablets, capsules, and dry syrups, with completion expected within three months. PROMESE/CAL is the national program responsible for centralized procurement and distribution of essential medicines and health supplies in the Dominican Republic. This international contract represents a key business development for Medico Remedies.

Medico Remedies Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut for all insiders, designated persons, and their immediate relatives starting from July 1st, 2026. It will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30th, 2026. This measure is standard practice to prevent potential misuse of unpublished price-sensitive information.

Medico Remedies Ltd has paid a total fine of ₹1,13,280 (₹56,640 each) to NSE and BSE for alleged non-compliance with Regulation 6(1) of the SEBI Listing Regulations for the period January 1 to February 17, 2026. The company received Show Cause Notices on May 20, 2026, and paid the fines on May 25, 2026. Medico Remedies stated that the non-compliance was inadvertently missed and assured future adherence. The company confirmed no material impact on its financials or operations.